ACM
RXRX icon

Aquatic Capital Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Aquatic Capital Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-9,300
Closed -$62K – 1701
2023
Q1 		$62K Buy
9,300
+6,300
+210% +$50K ﹤0.01% 844
2022
Q4 		$23K Buy
+3,000
New +$29.4K ﹤0.01% 1146

Other funds holding RXRX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
DCI
Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Aquatic Capital Management's RXRX Position: Q2 2023 in Review

Aquatic Capital Management sold out of Recursion Pharmaceuticals (RXRX) in Q2 2023, closing a stake of 9,300 shares — an estimated $62K sold.

Aquatic Capital Management first reported a position in RXRX in Q4 2022 and held it in 2 quarters. The position peaked at $62K in Q1 2023. 158 funds tracked by Wall St. Rank hold RXRX as of Q2 2023.

  • Aquatic Capital Management reported no remaining Recursion Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Aquatic Capital Management sold 9,300 Recursion Pharmaceuticals shares in Q2 2023, an estimated $62K.
  • Aquatic Capital Management first reported a position in Recursion Pharmaceuticals in Q4 2022 and held it in 2 quarters.
  • Aquatic Capital Management's Recursion Pharmaceuticals position peaked at $62K in Q1 2023.
  • 158 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2023.

Based on Aquatic Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.